WFDC2 and Myocardial fibrosis: The main findings of the present study are 1) higher HE4 serum levels (≥130 pmol/L) are robustly associated with adverse clinical outcomes and treatment futility following TAVI; 2) higher HE4 serum levels are associated with the presence of myocardial fibrosis at 1 to 3 months following the procedure.